CALCITONIN GENE-RELATED PEPTIDE RECEPTOR (CGRP-R) ANTAGONIST
Ajovy is approved by the Food and Drug Administration (FDA) to prevent migraine in adults. Ajovy is also referred to by its drug name, Fremanezumab-vfrm.
Ajovy is a biologic drug – a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Ajovy is also a member of a new class of drugs called calcitonin gene-related peptide receptor (CGRP-R) antagonists. Ajovy is believed to work by interfering with CGRP, a substance that dilates blood vessels and contributes to pain signals and inflammation.
How do I take it?
Prescribing information states that Ajovy is administered as a subcutaneous injection once a month or every three months.
Ajovy comes in prefilled, single-dose syringes.
The FDA-approved label for Ajovy lists injection site reactions as a common side effect.
Because Ajovy is a new drug, its long-term effects are not yet known.
For more details about this treatment, visit:
Ajovy.com – Teva
Ajovy Approved by FDA as Second CGRP Blocker for Migraine Prevention – Migraine.com